Abstract
The treatments of multiple myeloma (MM) have been made remarkable progress in recent years, and especially in 2015, FDA approved a number of new drugs for treatment of relapsed and refractory MM. At the 21th European Hematology Association Annual Meeting, the issue of MM has received a lot of attention. The recent progress of MM in this conference will be briefly introduced in this review. Key words: Multiple myeloma; Anti CD38 monoclonal antibody; Proteasome inhibitor; Autologous hematopoietic stem cell transplatation
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
